Regeneron Pharmaceuticals, Inc. director George L. Sing filed a Form 144 notice on November 17, 2026, disclosing a proposed sale of 1,000 shares of common stock on NASDAQ.
Key Highlights
- Proposed sale: George L. Sing, a director, intends to sell 1,000 shares of Regeneron common stock with an aggregate market value of $957,687.10.
- Acquisition history: The 1,000 shares to be sold were acquired on April 9, 1991, through a private acquisition from the issuer, paid in cash.
- Broker: The proposed sale is to be executed through Morgan Stanley Smith Barney LLC Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY 10004.
- Approximate sale date: The filing lists November 17, 2026 as the approximate date of sale.
- Shares outstanding: According to the filing, 101,630,713 shares of Regeneron common stock were outstanding at the time of filing.
- Prior sales in past 3 months: The filing discloses two prior sales by Sing: 1,000 shares sold on November 16, 2026 for gross proceeds of $960,264.40, and 21,129 shares sold on November 2, 2026 for gross proceeds of $20,376,359.76.
George L. Sing's Proposed Share Sale at Regeneron Pharmaceuticals
According to the Form 144 notice filed with the U.S. Securities and Exchange Commission on November 17, 2026, George L. Sing, identified in the filing as a director of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), is proposing to sell 1,000 shares of the company's common stock. The filing lists the aggregate market value of those shares at $957,687.10, with the approximate date of sale listed as November 17, 2026.
The filing discloses that the 1,000 shares subject to the proposed sale were originally acquired on April 9, 1991, through a private acquisition from the issuer, with payment made in cash on the same date. The proposed transaction is to be handled through Morgan Stanley Smith Barney LLC Executive Financial Services in New York, the filing states.
The Form 144 also requires disclosure of securities sold in the prior three months. According to the filing, Sing sold 1,000 shares of Regeneron common stock on November 16, 2026, generating gross proceeds of $960,264.40, and sold an additional 21,129 shares on November 2, 2026, with gross proceeds of $20,376,359.76. The filing was signed by George L. Sing and dated November 17, 2026. By signing, the filing states, the seller represented that he "does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed."
What Was Disclosed
A Form 144 notice filed November 17, 2026 by Regeneron director George L. Sing covers a proposed sale of 1,000 common shares valued at $957,687.10, alongside disclosure of two prior sales totaling 22,129 shares over the preceding three months.




Please wait processing your request...